Gene-editing drug VERVE-102 shows promise in reducing bad cholesterol in early trial

An experimental gene-editing therapy, VERVE-102, has shown positive results in a Phase I safety trial aimed at lowering bad cholesterol after a single infusion. Researchers published interim results this week from a study involving 35 patients in the New England Journal of Medicine. The findings indicate that VERVE-102 is safe, with no serious adverse events reported, although a mild increase in a liver enzyme was noted, suggesting minor liver injury. Participants receiving the highest dose experienced a 62% reduction in low-density lipoprotein (LDL) cholesterol, dropping to a mean of 78 mg per deciliter. This level of reduction could potentially lower the risk of cardiovascular disease significantly if maintained over a long period. The trial has provided up to 18 months of follow-up data, showing sustained LDL reductions across all subgroups.